Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype

Sidinh Luc, Jialiang Huang, Jennifer L. McEldoon, Ece Somuncular, Dan Li, Claire Rhodes, Shahan Mamoor, Serena Hou, Jian Xu, Stuart H. Orkin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

B cell CLL/lymphoma 11A (BCL11A) is a transcription factor and regulator of hemoglobin switching that has emerged as a promising therapeutic target for sickle cell disease and thalassemia. In the hematopoietic system, BCL11A is required for B lymphopoiesis, yet its role in other hematopoietic cells, especially hematopoietic stem cells (HSCs) remains elusive. The extensive expression of BCL11A in hematopoiesis implicates context-dependent roles, highlighting the importance of fully characterizing its function as part of ongoing efforts for stem cell therapy and regenerative medicine. Here, we demonstrate that BCL11A is indispensable for normal HSC function. Bcl11a deficiency results in HSC defects, typically observed in the aging hematopoietic system. We find that downregulation of cyclin-dependent kinase 6 (Cdk6), and the ensuing cell-cycle delay, correlate with HSC dysfunction. Our studies define a mechanism for BCL11A in regulation of HSC function and have important implications for the design of therapeutic approaches to targeting BCL11A.

Original languageEnglish (US)
Pages (from-to)3181-3194
Number of pages14
JournalCell Reports
Volume16
Issue number12
DOIs
StatePublished - Sep 20 2016

Fingerprint

B-Cell Lymphoma
Hematopoietic Stem Cells
Stem cells
Aging of materials
Phenotype
Defects
Hematopoietic System
Cells
Cyclin-Dependent Kinase 6
Lymphopoiesis
Regenerative Medicine
Thalassemia
Hematopoiesis
Sickle Cell Anemia
Cell- and Tissue-Based Therapy
Cell Cycle
Hemoglobins
Transcription Factors
Stem Cells
Down-Regulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Luc, S., Huang, J., McEldoon, J. L., Somuncular, E., Li, D., Rhodes, C., ... Orkin, S. H. (2016). Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype. Cell Reports, 16(12), 3181-3194. https://doi.org/10.1016/j.celrep.2016.08.064

Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype. / Luc, Sidinh; Huang, Jialiang; McEldoon, Jennifer L.; Somuncular, Ece; Li, Dan; Rhodes, Claire; Mamoor, Shahan; Hou, Serena; Xu, Jian; Orkin, Stuart H.

In: Cell Reports, Vol. 16, No. 12, 20.09.2016, p. 3181-3194.

Research output: Contribution to journalArticle

Luc, S, Huang, J, McEldoon, JL, Somuncular, E, Li, D, Rhodes, C, Mamoor, S, Hou, S, Xu, J & Orkin, SH 2016, 'Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype', Cell Reports, vol. 16, no. 12, pp. 3181-3194. https://doi.org/10.1016/j.celrep.2016.08.064
Luc S, Huang J, McEldoon JL, Somuncular E, Li D, Rhodes C et al. Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype. Cell Reports. 2016 Sep 20;16(12):3181-3194. https://doi.org/10.1016/j.celrep.2016.08.064
Luc, Sidinh ; Huang, Jialiang ; McEldoon, Jennifer L. ; Somuncular, Ece ; Li, Dan ; Rhodes, Claire ; Mamoor, Shahan ; Hou, Serena ; Xu, Jian ; Orkin, Stuart H. / Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype. In: Cell Reports. 2016 ; Vol. 16, No. 12. pp. 3181-3194.
@article{1c634d971d354cc09c22d6342d7f92c1,
title = "Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype",
abstract = "B cell CLL/lymphoma 11A (BCL11A) is a transcription factor and regulator of hemoglobin switching that has emerged as a promising therapeutic target for sickle cell disease and thalassemia. In the hematopoietic system, BCL11A is required for B lymphopoiesis, yet its role in other hematopoietic cells, especially hematopoietic stem cells (HSCs) remains elusive. The extensive expression of BCL11A in hematopoiesis implicates context-dependent roles, highlighting the importance of fully characterizing its function as part of ongoing efforts for stem cell therapy and regenerative medicine. Here, we demonstrate that BCL11A is indispensable for normal HSC function. Bcl11a deficiency results in HSC defects, typically observed in the aging hematopoietic system. We find that downregulation of cyclin-dependent kinase 6 (Cdk6), and the ensuing cell-cycle delay, correlate with HSC dysfunction. Our studies define a mechanism for BCL11A in regulation of HSC function and have important implications for the design of therapeutic approaches to targeting BCL11A.",
author = "Sidinh Luc and Jialiang Huang and McEldoon, {Jennifer L.} and Ece Somuncular and Dan Li and Claire Rhodes and Shahan Mamoor and Serena Hou and Jian Xu and Orkin, {Stuart H.}",
year = "2016",
month = "9",
day = "20",
doi = "10.1016/j.celrep.2016.08.064",
language = "English (US)",
volume = "16",
pages = "3181--3194",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "12",

}

TY - JOUR

T1 - Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype

AU - Luc, Sidinh

AU - Huang, Jialiang

AU - McEldoon, Jennifer L.

AU - Somuncular, Ece

AU - Li, Dan

AU - Rhodes, Claire

AU - Mamoor, Shahan

AU - Hou, Serena

AU - Xu, Jian

AU - Orkin, Stuart H.

PY - 2016/9/20

Y1 - 2016/9/20

N2 - B cell CLL/lymphoma 11A (BCL11A) is a transcription factor and regulator of hemoglobin switching that has emerged as a promising therapeutic target for sickle cell disease and thalassemia. In the hematopoietic system, BCL11A is required for B lymphopoiesis, yet its role in other hematopoietic cells, especially hematopoietic stem cells (HSCs) remains elusive. The extensive expression of BCL11A in hematopoiesis implicates context-dependent roles, highlighting the importance of fully characterizing its function as part of ongoing efforts for stem cell therapy and regenerative medicine. Here, we demonstrate that BCL11A is indispensable for normal HSC function. Bcl11a deficiency results in HSC defects, typically observed in the aging hematopoietic system. We find that downregulation of cyclin-dependent kinase 6 (Cdk6), and the ensuing cell-cycle delay, correlate with HSC dysfunction. Our studies define a mechanism for BCL11A in regulation of HSC function and have important implications for the design of therapeutic approaches to targeting BCL11A.

AB - B cell CLL/lymphoma 11A (BCL11A) is a transcription factor and regulator of hemoglobin switching that has emerged as a promising therapeutic target for sickle cell disease and thalassemia. In the hematopoietic system, BCL11A is required for B lymphopoiesis, yet its role in other hematopoietic cells, especially hematopoietic stem cells (HSCs) remains elusive. The extensive expression of BCL11A in hematopoiesis implicates context-dependent roles, highlighting the importance of fully characterizing its function as part of ongoing efforts for stem cell therapy and regenerative medicine. Here, we demonstrate that BCL11A is indispensable for normal HSC function. Bcl11a deficiency results in HSC defects, typically observed in the aging hematopoietic system. We find that downregulation of cyclin-dependent kinase 6 (Cdk6), and the ensuing cell-cycle delay, correlate with HSC dysfunction. Our studies define a mechanism for BCL11A in regulation of HSC function and have important implications for the design of therapeutic approaches to targeting BCL11A.

UR - http://www.scopus.com/inward/record.url?scp=84989884580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989884580&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2016.08.064

DO - 10.1016/j.celrep.2016.08.064

M3 - Article

VL - 16

SP - 3181

EP - 3194

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 12

ER -